Copyright
©The Author(s) 2024.
World J Nephrol. Dec 25, 2024; 13(4): 95761
Published online Dec 25, 2024. doi: 10.5527/wjn.v13.i4.95761
Published online Dec 25, 2024. doi: 10.5527/wjn.v13.i4.95761
Table 1 Criteria for diagnosis of diabetes
| Tests | Results |
| Fasting plasma glucose (fasting is defined as no caloric intake for at least eight hours)1 | ≥ 126 mg/dL (7.0 mmol/L) |
| Or, 2-hour plasma glucose during OGTT (the test should be performed as described by the World Health Organization, using a glucose load containing the equivalent of 75-g anhydrous glucose dissolved in water)1 | ≥ 200 mg/dL (11.1 mmol/L) |
| Or, HbA1c (the test should be performed in a laboratory using a method that is NGSP certified and standardized to the DCCT assay)1 | ≥ 6.5% (48 mmol/mol) |
| Or, in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose | ≥ 200 mg/dL (11.1 mmol/L) |
Table 2 Estimated glomerular filtration rate equations
| Names | Equations | |||
| Cock-Croft Gault (mL/min) | eGFR = [(140-age) × weight]/(72 × Scr) (× 0.85 if female) | |||
| MDRD (mL/min/1.73 m²) | eGFR = 186 × (Scr)-1.154 × (age)-0.203 × (0.742 if female) × (1.210 if African American) | |||
| CKD-EPI 2021 creatinine (mL/min/1.73 m²) | Female | Scr ≤ 0.7 | eGFR = 142 × (Scr/0.7)-0.241 × 0.9938age × 1.012 | |
| Scr > 0.7 | eGFR = 142 × (Scr/0.7)-1.200 × 0.9938age × 1.012 | |||
| Male | Scr ≤ 0.9 | eGFR = 142 × (Scr/0.9)-0.302 × 0.9938age | ||
| Scr > 0.9 | eGFR = 142 × (Scr/0.9)-1.200 × 0.9938age | |||
| CKD-EPI 2012 cystatin C (mL/min/1.73 m²) | Female | Scys ≤ 0.8 | eGFR = 133 × (Scys/0.8)– 0.499 × 0.996age × 0.932 | |
| Scys > 0.8 | eGFR = 133 × (Scys/0.8)– 1.328 × 0.996age × 0.932 | |||
| Male | Scys ≤ 0.8 | eGFR = 133 × (Scys/0.8)– 0.499 × 0.996age | ||
| Scys > 0.8 | eGFR = 133 × (Scys/0.8)– 1.328 × 0.996age | |||
| CKD-EPI 2021 creatinine-cystatin C (mL/min/1.73 m²) | Female | Scr ≤ 0.7 | Scys ≤ 0.8 | eGFR = 135 × (Scr/0.7)-0.219 × (Scys/0.8)-0.323 × 0.9961age × 0.963 |
| Scys > 0.8 | eGFR = 135 × (Scr/0.7)-0.219 × (Scys/0.8)-0.778 × 0.9961age × 0.963 | |||
| Scr > 0.7 | Scys ≤ 0.8 | eGFR = 135 × (Scr/0.7)-0.544 × (Scys/0.8)-0.323 × 0.9961age × 0.963 | ||
| Scys > 0.8 | eGFR = 135 × (Scr/0.7)-0.544 × (Scys/0.8)-0.778 × 0.9961age × 0.963 | |||
| Male | Scr ≤ 0.9 | Scys ≤ 0.8 | eGFR = 135 × (Scr/0.9)-0.144 × (Scys/0.8)-0.323 × 0.9961age | |
| Scys > 0.8 | eGFR = 135 × (Scr/0.9)-0.144 × (Scys/0.8)-0.778 × 0.9961age | |||
| Scr > 0.9 | Scys ≤ 0.8 | eGFR = 135 × (Scr/0.9)-0.544 × (Scys/0.8)-0.323 × 0.9961age | ||
| Scys > 0.8 | eGFR = 135 × (Scr/0.9)-0.544 × (Scys/0.8)-0.778 × 0.9961age | |||
Table 3 Chronic kidney disease stages
| Terms | eGFR (mL/min/1.73 m2) |
| Normal or high | ≥ 90 |
| Mildly decreased | 60-89 |
| Mildly to moderately decreased | 45-59 |
| Moderately to severely decreased | 30-44 |
| Severely decreased | 15-29 |
| Kidney failure | < 15 |
Table 4 Clinical and laboratory characteristics of the study subjects
| Characteristics | Type 2 diabetic | P value | Characteristics | Type 2 diabetic | P value | |||
| Yes (n = 47) | No (n = 46) | Yes (n = 47) | No (n = 46) | |||||
| Gender n, (%) | Male | 15 (31.9) | 18 (39.1) | 0.47 | HbA1c (%) | 7.3 ± 1.7 | 5.8 ± 0.93 | < 0.011 |
| Female | 32 (68.1) | 28 (60.9) | Glucose (mmol/L) | 7.2 ± 2.7 | 5.5 ± 0.6 | < 0.011 | ||
| Average age (years) | 71 ± 1.0 | 71 ± 1.2 | 0.82 | Total cholesterol (mmol/L) | 5.6 ± 0.9 | 5.6 ± 1.2 | 0.8 | |
| Weight (kg) | 59.4 ± 13.4 | 57.3 ± 9.3 | 0.4 | Triglycerides (mmol/L) | 2.3 ± 0.9 | 2.1 ± 1.3 | 0.6 | |
| BMI (kg/m2) | 24.3 ± 4.4 | 23.0 ± 2.7 | 0.08 | HDL-C (mmol/L) | 1.1 ± 0.27 | 1.1 ± 0.3 | 0.8 | |
| SBP (mmHg) | 133 ± 14.2 | 129.7 ± 10.6 | 0.2 | LDL-C (mmol/L) | 3.6 ± 0.9 | 3.6 ± 1.0 | 1 | |
| DBP (mmHg) | 82.2 ± 4.5 | 81.4 ± 5.0 | 0.4 | Uric acid (μmol/L) | 330 ± 75.6 | 315 ± 68.4 | 0.3 | |
| Scr (µmol/L) | 84.9 ± 26.3 | 77.9 ± 20.1 | 0.15 | Scys (mg/L) | 1.3 ± 0.4 | 1.22 ± 0.3 | 0.3 | |
| ACR (mg/g) | 17.4 (3.9 – 8632.3)2 | 13.5 (4 – 252.8)2 | 0.11 | |||||
Table 5 Estimated glomerular filtration rate values and its correlation with serum cystatin C concentration
| eGFR (mL/min/1.73 m2) | Type 2 diabetes | P value | Correlation between eGFR values and Scys | ||
| Yes (n = 47) | No (n = 46) | r | P1 value | ||
| Cockcroft-Gault | 64.7 ± 22.5 | 67.3 ± 20.6 | 0.56 | -0.47 | < 0.01 |
| MDRD | 72 ± 0.19 | 80 ± 0.17 | 0.06 | -0.59 | < 0.01 |
| CKD-EPI 2021 creatinine | 102.8 ± 32.8 | 109.1 ± 30.9 | 0.34 | -0.59 | < 0.01 |
| CKD-EPI 2012 cystatin C | 55.6 ± 17.1 | 58.7 ± 15.4 | 0.35 | -0.86 | < 0.01 |
| CKD-EPI 2021 creatinine-cystatin C | 66.8 ± 14.6 | 70.4 ± 13.8 | 0.23 | -0.91 | < 0.01 |
Table 6 The agreements between estimated glomerular filtration rate equations
| Equations | CKD-EPI 2021 creatinine-cystatin C (mL/min/1.73m2) | Kappa coefficients (P1 value) | ||
| < 60 | ≥ 60 | |||
| Cockcroft-Gault (mL/min/1.73 m2) | < 60 | 19 | 20 | 0.43 (P < 0.001) |
| ≥ 60 | 4 | 50 | ||
| MDRD (mL/min/1.73 m2) | < 60 | 15 | 3 | 0.66 (P < 0.001) |
| ≥ 60 | 8 | 67 | ||
| CKD-EPI 2021 creatinine (mL/min/1.73 m2) | < 60 | 9 | 0 | 0.49 (P < 0.001) |
| ≥ 60 | 14 | 70 | ||
| CKD-EPI 2012 cystatin C (mL/min/1.73 m2) | < 60 | 19 | 20 | 0.44 (P < 0.001) |
| ≥ 60 | 4 | 50 | ||
Table 7 Related factors that affect the estimated glomerular filtration rate decline in elderly diabetic patients
| Characteristics (n, %) | eGFR decline | P value | Characteristics (n, %) | eGFR decline | P value | ||||||||||
| Yes (n = 14) | No (n = 33) | Yes (n = 14) | No (n = 33) | ||||||||||||
| Gender | Male | 4 (26.7) | 11 (73.3) | 0.7 | BMI | Normal | 6 (28.6) | 15 (71.4) | 0.2 | ||||||
| Female | 10 (31.2) | 22 (68.8) | Overweight, obese | 8 (30.8) | 18 (69.2) | ||||||||||
| Hypertension | Yes | 6 (35.3) | 11 (64.7) | 0.53 | Uric acid | Increased | 1 (10.0) | 9 (90.0) | 0.15 | ||||||
| No | 8 (26.7) | 22 (73.3) | Normal | 13 (35.1) | 24 (64.9) | ||||||||||
| ACR | Increased | 5 (35.7) | 9 (27.3) | 0.6 | Triglycerides | Increased | 9 (31.0) | 20 (69.0) | 0.24 | ||||||
| Normal | 9 (64.3) | 24 (72.7) | Normal | 5 (27.8) | 13 (72.2) | ||||||||||
| HDL-C | Decreased | 9 (39.1) | 14 (60.9) | 0.18 | LDL-C | Increased | 11 (26.8) | 30 (73.2) | 0.26 | ||||||
| Normal | 5 (20.8) | 19 (79.2) | Normal | 3 (50.0) | 3 (50.0) | ||||||||||
| The relationship of declined eGFR and the correlation of eGFR with glucose, HbA1c, total cholesterol, and exercise (n = 47) | |||||||||||||||
| Characteristics | Declined eGFR | eGFR (mL/min/1.73 m2) | |||||||||||||
| OR | 95%CI | Pa value | r | Pb value | |||||||||||
| Glucose (mmol/L) | 1.6 | 1.1-2.5 | 0.04 | -0.46 | 0.001 | ||||||||||
| HbA1c (%) | 1.7 | 1.1-2.6 | 0.013 | -0.47 | 0.001 | ||||||||||
| Total cholesterol (mmol/L) | 0.24 | 0.06-0.9 | 0.029 | 0.341 | 0.019 | ||||||||||
| Exercise (regular, irregular) | 0.16 | 0.03-0.81 | 0.017 | N/A | N/A | ||||||||||
| Multivariate logistic regression between glucose, HbA1c, total cholesterol, exercise and declined eGFR (n = 47) | |||||||||||||||
| Characteristics | Declined eGFR | ||||||||||||||
| β | OR | 95%CI | Pc value | ||||||||||||
| Glucose (mmol/L) | -0.203 | 0.816 | 0.550-1.212 | 0.315 | |||||||||||
| HbA1c (%) | -0.456 | 0.634 | 0.330-1.217 | 0.171 | |||||||||||
| Total cholesterol (mmol/L) | 1.141 | 3.130 | 1.000-9.793 | 0.05 | |||||||||||
| Exercise (regular, irregular) | 2.844 | 17.178 | 1.409-209.369 | 0.026 | |||||||||||
| Multiple linear regression between glucose, HbA1c, total cholesterol and eGFR values (n = 47) | |||||||||||||||
| Characteristics | eGFR (mL/min/1.73 m2) | ||||||||||||||
| β | r | r2 | Pd value | ||||||||||||
| Glucose (mmol/L) | -2.248 | -0.366 | 0.13 | 0.026 | |||||||||||
| HbA1c (%) | -1.591 | -0.162 | 0.02 | 0.332 | |||||||||||
| Total cholesterol (mmol/L) | 4.503 | 1.949 | 3.79 | 0.058 | |||||||||||
- Citation: Tran TTT, Ha TK, Phan NM, Le MV, Nguyen TH. Detection of decline in estimated glomerular filtration rate in patients with type 2 diabetes by cystatin C-based equations. World J Nephrol 2024; 13(4): 95761
- URL: https://www.wjgnet.com/2220-6124/full/v13/i4/95761.htm
- DOI: https://dx.doi.org/10.5527/wjn.v13.i4.95761
